Magnesium Sulfate for Adjuvant Analgesia in Pediatric Burn Dressing Changes: a Pilot Study
Hennepin Healthcare Research Institute
Summary
Prospective feasibility trial utilizing adjuvant magnesium sulfate for analgesia/sedation during pediatric sedated burn dressing changes, which is ultimately hypothesized to decrease ketamine and/or sedative requirements.
Description
Pediatric patients (n=10) suffering severe burn, admitted to the burn unit at Hennepin County Medical Center (Minneapolis, MN) meeting specific inclusion/exclusion criteria will be randomized daily to either intravenous magnesium sulfate (50 mg/kg, max 2 g) or placebo (normal saline) for up to 5 sedated burn dressing changes. Primary aims will be to evaluate safety/feasibility to guide a future larger randomized controlled trial.
Eligibility
- Age range
- 3–18 years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * \< 18 years old at time of randomization completion * admission to HCMC Burn Unit * Projected multi-day sedated dressing change requirement * Intention for IV Ketamine as primary analgosedative agent Exclusion Criteria: * age \< 3 years (may lower pending FDA discussions) * Evidence of hypermagnesemia - pre-study serum Mg2+ level \> 2.5 mg/dL * Evidence of renal dysfunction - serum Cr level \> 1.5x hospital upper limit normal for age * Presence of neuromuscular disease (specifically myasthenia gravis), underlying bradyarrhythmia or heart block * Bronchospastic disease…
Interventions
- Drugmagnesium sulfate
IV Magnesium Sulfate 50 mg/kg (max 2 grams) over 20 minutes given immediately prior to initiation of daily sedated dressing change
- DrugNormal Saline (0.9% NaCl)
Normal Saline given in equivalent volume as study drug over 20 minutes, immediately prior to initiation of sedated dressing change
Location
- Hennepin County Medical CenterMinneapolis, Minnesota